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Decreased serum level of NgF in alcohol-dependent 
patients with declined executive function
Abstract: The role of neurotrophic factors has been highlighted as a cause of decline in the 
cognitive function of alcohol-dependent patients. It is known that nerve-growth factor (NGF), 
one of the neurotrophins, is related to the growth and differentiation of nerve cells, as well as 
to a decline in cognitive function. The purpose of this study was to investigate the relation-
ship between decreased NGF levels and cognitive decline in alcohol-dependent patients. The 
serum concentration of NGF was measured in 38 patients with chronic alcohol dependence, 
and several neuropsychological tests were also performed for cognitive function assessment. 
The results indicated a significant correlation between serum NGF level and the trail-making 
test part B, which evaluates executive function, but did not show a significant correlation with 
other cognitive function tests. An increased serum level of NGF was associated with a decreased 
completion time in the trail-making test B, and this finding indicates that a high serum level of 
NGF is related to greater executive function. This finding may imply a protective role of NGF 
in preventing neuron damage among patients with alcohol dependence. Larger controlled studies 
will be necessary in the future to investigate this issue further.
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Introduction
It has been well acknowledged that alcohol-dependent patients experience a decline in 
their cognitive function even after the cessation of alcohol consumption.1,2 Although 
learning ability and memory are recovered with time, abstract reasoning, problem-
solving skill, perception, and motor function are lower than in a normal control group 
after 1 year of abstinence.3
The cognitive decline in alcohol-dependent patients that continues after absti-
nence is most likely due to neuronal damage caused by alcohol.4–6 Recently, the 
role of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and 
nerve-growth factor (NGF), has received focus among several factors that are involved 
in the protecting mechanism of alcohol-induced neuronal damage.7
NGF is one of the neurotrophins involved in the growth and differentiation of 
nerve cells and prevention of damage to mature neurons. It may also play an important 
role in protecting from alcohol-induced neurotoxicity.8–11 There are several studies in 
alcohol-dependent patients with different findings on NGF. Heberlein et al suggested 
that NGF rises during acute alcohol intoxication and declines during the withdrawal 
period.12 Other studies reported that the NGF level drops in patients who have been 
abstinent for longer than 30 days when compared to a control group. In particular, 
those who had a family history of alcoholism showed a greater decrease.13 It seems 
that NGF increased in the intoxication period for the compensation of the neurotoxic 
effects of alcohol, but eventually decreased in chronic alcohol-dependent patients, 
hwallip Bae1
Youngsun ra1
changwoo han2
Dai-Jin Kim3
1Department of Psychiatry, Myongji 
hospital, goyang, 2Department 
of Psychiatry, Keyo hospital, 
Uiwang, 3Department of Psychiatry, 
seoul st Mary’s hospital, college 
of Medicine, catholic University 
of Korea, seoul, south Korea
correspondence: Dai-Jin Kim
Department of Psychiatry, seoul st 
Mary’s hospital, college of Medicine, 
catholic University of Korea, 
222 Banpo-daero, seocho-gu, 
seoul 137-701, south Korea
Tel +82 2 2258 6933
Fax +82 2 594 3870
email kdj922@chol.com Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2154
Bae et al
even in the abstinence period. The number of studies is not 
sufficient yet for consistent results.
Among a handful of studies on the relationship between 
NGF and patients’ cognitive function, Jockers-Scherübl 
et al reported that even though alcohol-dependent patients 
had increased levels of serum NGF and the levels were 
even higher with the symptoms of withdrawal delirium, the 
serum NGF level in patients with persistent amnesic disorder 
(  Korsakoff’s syndrome) showed no changes and was differ-
ent from the control group.14
Furthermore, in experiments with animals, when rats 
were administered with NGF after they were withdrawn 
from chronic treatment with alcohol, their spatial learning 
recovered and the length density of hippocampal cholinergic 
fibers was restored.15
Recent studies have shown the value of NGF in inves-
tigating the pathogenesis and its potential as a biological 
marker in alcohol-dependent patients.13 Also, animal stud-
ies have demonstrated its potential use in long-term 
  treatment.15 As mentioned earlier, however, there are few 
studies that have investigated the correlation between NGF 
and cognitive function. Therefore, the authors measured the 
serum NGF level in alcohol-dependent patients during the 
abstinence period and then conducted several neuropsycho-
logical tests as a cognitive function-evaluation tool in order 
to determine the correlation between them.
Materials and methods
subjects
The subjects in this study were 38 patients admitted to the 
Alcohol Treatment Center at a psychiatric institution in   
Gyeonggi Province, South Korea. The patients were diag-
nosed with alcohol dependence by two psychiatrists accord-
ing to Diagnostic and Statistical Manual of Mental Disorders 
(DSM)-IV criteria. The age range was 38–61 years, and 
patients with psychiatric disorders other than depression were 
excluded from the study. Exclusion criteria also included 
other substance abuse, history of severe head injury, and 
neurological disorders. Patients in their detoxification period 
were not included either. Also, patients with withdrawal 
symptoms were excluded. Patients with a confirmed absti-
nence period of at least 1 week by admission in a closed ward 
were allowed to participate in the study.
None of the participants were on antidepressant or antipsy-
chotic treatment, although most of them had been prescribed 
either antianxiolytics or sleeping pills at low doses, hepato-
tonics, and multivitamins. Patients were taking the anxiolytic 
lorazepam 1 mg or less and the hypnotic zolpidem 10 mg 
or less. Multivitamins were mainly vitamins B1 and B6. The 
ingredients of hepatotonics and the exact numbers of subjects 
who were taking these medications were unascertainable.
Demographic and clinical characteristics of the subjects 
are displayed in Table 1. All subjects were men. They agreed 
to participate in the study and signed an informed consent 
form after the researchers explained the study details. The 
study was approved by the Institutional Review Board of 
Seoul St Mary’s Hospital, Seoul, South Korea.
clinical assessments
A survey was used to collect the demographic variables, 
including subjects’ age, education, age of first alcohol 
consumption, frequency of alcohol consumption, average 
amount of consumed alcohol, and abstinence periods of 
alcohol. Neuropsychological tests – verbal fluency, word-
list memory test, word-list recall, word-list recognition, 
constructional praxis, constructional recall, Boston naming 
test, Mini Mental Status Examination – Korean (MMSE-K), 
and trail-making test A and B – were used to evaluate cog-
nitive function. These neuropsychological tests evaluate 
language, memory, constructional ability, and executive 
function. Two clinical psychologists conducted the tests 
on each patient.
Table 1 correlations among demographics, alcohol-related data, NgF, and TMT
Mean ± SD TMT-A TMT-B NGF
Demographic data
age, years 51.18±6.38 0.253 0.173 -0.157
Alcohol related data
Onset age of drinking 21.15±7.98 0.461** 0.305 0.116
Frequency of alcohol consumed (per week) 4.15±2.21 0.114 -0.263 -0.122
Daily amount of alcohol consumed (standard drink) 3.18±2.14 0.024 0.066 -0.322*
First age of alcohol treatment 38.52±8.22 0.095 0.103 0.050
Total abstinence period, days 185.66±474.35 -0.038 -0.065 -0.166
Notes: *P0.05; **P0.01.
Abbreviations: TMT, trail-making test; NgF, nerve-growth factor; sD, standard deviation.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
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enzyme-linked immunosorbent assay
The subjects’ blood was drawn by a nurse between 10 and 
11 am. Ten milliliters of blood was collected into an ethyl-
enediaminetetraacetic acid-coated tube, immediately centri-
fuged until the serum was separated, and  stored at -80°C 
for further analysis.
NGFs were measured using Human Adipokine Magnetic 
Bead Panels 2 – Endocrine Multiplex Assay (HADK2MAG-
61K), manufactured by Millipore (Seoul, South Korea). The 
test was conducted according to the standard guidelines sug-
gested by the manufacturer. The concentration of the plates was 
corrected through the dilution factor of the standard curve.
statistical analysis
A Pearson correlation analysis was used to determine the 
correlation among the demographic variables, the result of 
neuropsychological tests, and NGF. Student’s t-test was used 
to determine whether there was a difference in the serum level 
of NGF or the results of neuropsychological tests between 
patients with a positive and negative family history. Like-
wise, the t-test was used for comparison between patients 
who were positive and negative for withdrawal-symptom 
history. Analysis of variance (ANOVA) was conducted to 
determine if there was a difference in the serum level of 
NGF or the results of neuropsychological test by education 
level (junior high, high school, professional college, 4-year 
university). Windows SPSS version 16.0 was used as the 
software tool for statistical analysis, and the significance 
level was set at P0.05.
Results
enzyme-linked immunosorbent assay
The mean serum level of NGF and standard deviation was 
26.74±10.08 pg/mL.
Demographic characteristics 
and alcohol-related data
There were 30 patients with a family history of alcoholism 
among the 38 patients. The number of patients with a history 
of alcohol-withdrawal symptoms was 32. The t-test revealed 
no significant difference in the serum level of NGF or the 
results of neuropsychological testing according to family 
history or alcohol-withdrawal symptom history.
The average duration of education was approximately 
10 years. ANOVA showed no significant difference in the 
results from neuropsychological tests or the level of NGF by 
education level. The results of the Pearson correlation test of 
age and other alcohol-related data are presented in Table 1. 
No significant correlation with either neuropsychological 
test results or NGF level was shown for age. However, in 
alcohol-related data, the onset age of drinking had a posi-
tive correlation with trail-making test A, and the amount of 
alcohol consumed daily had a negative correlation with NGF 
serum level (Table 1).
association between NgF and 
neuropsychological test in patients 
with alcohol dependence
Table 2 shows the association between NGF and neurop-
sychological test results in alcohol-dependent patients. The 
results revealed no significant correlation between levels 
of NGF and the neuropsychological test results, except the 
trail-making test B. The correlation between NGF and the 
trail-making test B was significant (r=-0.324, P=0.046).
correlation between NgF 
and trail-making test indices
Associations between NGF and derived trail-making test 
indices B – A, B/A, and B – A/A were examined. Significant 
correlations between NGF level and derived trail-making test 
indices B – A, B/A, and B – A/A were also revealed from 
the investigation (Table 3).
Discussion
The purpose of this study was to investigate the relationship 
between the level of serum NGF and the decline in cognitive 
function of alcohol-dependent patients during the abstinence 
period. Among several cognitive function tests, the trail-  making 
test B and NGF level demonstrated significant correlation. The 
increased NGF was associated with a lower trail-making test 
B score, indicating faster performance speed.
Table 2 correlations between NgF and neuropsychological tests   
for cognitive function evaluation
Neuropsychological tests Mean ± SD NGF r
Verbal fluency 15.29±3.67 0.173
Word-list memory 18.13±4.03 0.041
Word-list recall 6.45±2.13 -0.070
Word-list recognition 9.34±0.94 -0.038
constructional praxis 10.42±1.18 0.050
constructional recall 8.66±2.53 -0.011
Boston naming test 12.18±1.92 -0.084
MMse-K 26.84±3.11 0.134
Trail making test a 50.87±24.57 -0.101
Trail making test B 190.74±91.33 -0.324*
Note: *P0.05.
Abbreviations: NgF, nerve-growth factor; sD, standard deviation; MMse-K, Mini-
Mental state examination – Korean.Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2156
Bae et al
The trail-making test includes motor components as well 
as complex visual scanning, so it can be used to test visual 
motor tracking and such abilities as general attention and 
psychomotor speed.16,17 Since the trail-making test B requires 
more complex mental activity than test A, it is known to be 
more sensitive to brain damage.18,19
In addition, there have been attempts in several studies to 
locate brain lesions or identify impairment in specific brain 
functions based on the difference score (A – B), score ratio 
(A/B), and proportional score (B – A/A). Derived indices 
especially indicated impairment in executive function.20–22
In this study, all derived indices also displayed significant 
correlation with the NGF serum level. This finding indicates 
that executive functions of alcohol-dependent patients have 
significant correlations with NGF.18–20 In other words, the 
NGF level was higher in patients with higher executive func-
tion, which is in agreement with research findings that NGF 
prevents neuronal cell loss and atrophy in neurodegenerative 
disorders, such as Alzheimer’s disease.7,23,24 It also agrees 
with research findings that NGF protects nerve cells from 
neurotoxicity due to alcohol.6,8–11,15
In the study of Jockers-Scherübl et al the serum NGF level 
was higher in alcohol-dependent patients than in the control 
group.14 In the present study, the daily amount of alcohol 
consumed showed a negative correlation with NGF levels 
(Table 1), which means that more alcohol intake led to lower 
levels of NGF. However, considering Jockers-Scherübl et al’s 
qualified 8 days of withdrawal, and the fact that patients’ mean 
abstinence period was more than 185 days in our study, we 
can speculate the NGF level rise during the early withdrawal 
period was for neuroprotection, but afterwards, especially for 
the cognitive dysfunctioning patients, low levels of serum 
NGF were observed. In the study of Jockers-Scherübl et al 
patients with amnesic disorder (Korsakoff’s syndrome) had 
similar levels of serum NGF as the control group, which is in 
agreement with the results of the present study.14
Therefore, in addition to the confirmation of the neuro-
protective effects of NGF in alcohol-dependent patients, its 
role as a stage marker in alcohol-related diseases mentioned 
by Jockers-Scherübl et al and its therapeutic effect shown 
in Lukoyanov et al’s experiments with animals are valuable 
findings that should be further investigated.15
The daily amount of consumed alcohol had a significant 
negative correlation with the NGF level among the demo-
graphic data related to alcohol (Table 1). This finding 
indicates that in general, the greater the amount of alcohol 
consumed per day the lower the level of NGF. Also, the daily 
amount of consumed alcohol had a greater influence on the 
NGF level than the duration of alcohol dependence, absti-
nence period, family history, or withdrawal symptoms.
Limitations of this study were a lack of comparison 
between alcohol-dependent patients and the control group, 
a relatively small study population, and a subject group 
comprised entirely of males. Also, an investigation of 
smoking history was not conducted. There are previous 
studies on nicotine’s effect on cognitive function or level of 
NGF.25–27 Therefore, the possibility that nicotine use affects 
executive function or serum levels of NGF in alcohol-
dependent patients exists.
Although they took neither antidepressants nor antipsy-
chotic medications, most of the patients were taking multivi-
tamins, hepatotonics, and low dose of anxiolytics or sleeping 
pills. The negative effect of benzodiazepine on cognitive 
function and positive effects of vitamin A, D, or B complex 
on cognition are well known.28–30 However, the influences of 
these medications were not considered. As far as we know, 
the effect of hepatotonics on cognitive function is unknown, 
and these drugs’ effect on NGF is not known either, except a 
few studies of vitamin A or B12’s effect on NGF.31,32
In addition to this, it is difficult to know from this study 
how long the NGF serum level increase persists during   
the abstinence period, because a check of NGF levels was 
done only once in this study. Therefore, this is considered 
one of the limitations of this study. Future studies should 
take these points into consideration. We recommend further 
studies investigate the therapeutic effect of NGF in patients 
with declined cognitive function.
Acknowledgment
The study was supported by a grant from the Korean Health 
Technology R&D Project, Ministry of Health and Welfare, 
South Korea (HI11C13320000).
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Eckardt MJ, Stapleton JM, Rawlings RR, Davis EZ, Grodin DM. 
  Neuropsychological functioning in detoxified alcoholics between 18 
and 35 years of age. Am J Psychiatry. 1995;152(1):53–59.
2.  Kopera M, Wojnar M, Brower K, et al. Cognitive functions in abstinent 
alcohol-dependent patients. Alcohol. 2012;46(7):665–671.
Table 3 correlations between NgF- and TMT-derived indices
Variable TMT A TMT B TMT B – A TMT B/A TMT B – A/A
NgF -0.101 -0.326* -0.351* -0.358* -0.358*
Note: *P0.05.
Abbreviations: TMT, trail-making test; NgF, nerve-growth factor.Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing   
on concise rapid reporting of clinical or pre-clinical studies on a   
range of neuropsychiatric and neurological disorders. This journal   
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS,   
and is the official journal of The International Neuropsychiatric 
  Association (INA). The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.
Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2157
Decreased NgF in alcoholics with declined executive function
  3.  Fein G, Bachman L, Fisher S, Davenport L. Cognitive impairments in 
abstinent alcoholics. West J Med. 1990;152(5):531–537.
  4.  Tateno M, Saito T. Biological studies on alcohol-induced neuronal 
damage. Psychiatry Investig. 2008;5(1):21–27.
  5.  Miller MW. Limited ethanol exposure selectively alters the proliferation 
of precursor cells in the cerebral cortex. Alcohol Clin Exp Res. 1996; 
20(1):139–143.
  6.  Nixon K, Crews FT. Binge ethanol exposure decreases neurogenesis 
in adult rat hippocampus. J Neurochem. 2002;83(5):1087–1093.
  7.  Connor B, Dragunow M. The role of neuronal growth factors in neu-
rodegenerative disorders of the human brain. Brain Res Brain Res Rev. 
1998;27(1):1–39.
  8.  Seabold GK, Luo J, Miller MW. Effect of ethanol on neurotrophin-
mediated cell survival and receptor expression in cultures of cortical 
neurons. Brain Res Dev Brain Res. 1998;108(1–2):139–145.
  9.  Heaton MB, Mitchell JJ, Paiva M. Overexpression of NGF amelio-
rates ethanol neurotoxicity in the developing cerebellum. J Neurobiol. 
2000;45(2):95–104.
  10.  Moore DB, Madorsky I, Paiva M, Barrow Heaton M. Ethanol exposure 
alters neurotrophin receptor expression in the rat central nervous system: 
effects of prenatal exposure. J Neurobiol. 2004;60(1):101–113.
  11.  Moore DB, Madorsky I, Paiva M, Barrow Heaton M. Ethanol exposure 
alters neurotrophin receptor expression in the rat central nervous system: 
effects of neonatal exposure. J Neurobiol. 2004;60(1):114–126.
  12.  Heberlein A, Bleich S, Bayerlein K, et al. NGF plasma levels increase 
due to alcohol intoxication and decrease during withdrawal. Psychoneu-
roendocrinology. 2008;33(7):999–1003.
  13.  Yoon SJ, Roh S, Lee H, et al. Possible role of nerve growth factor 
in the pathogenesis of alcohol dependence. Alcohol Clin Exp Res. 
2006;30(6):1060–1065.
  14.  Jockers-Scherübl MC, Bauer A, Kuhn S, et al. Nerve growth factor in 
serum is a marker of the stage of alcohol disease. Neurosci Lett. 2007; 
419(1):78–82.
  15.  Lukoyanov NV, Pereira PA, Paula-Barbosa MM, Cadete-Leite A. Nerve 
growth factor improves spatial learning and restores hippocampal cho-
linergic fibers in rats withdrawn from chronic treatment with ethanol. 
Exp Brain Res. 2003;148(1):88–94.
  16.  Crowe SF. The differential contribution of mental tracking, cognitive 
flexibility, visual search, and motor speed to performance on parts A 
and B of the Trail Making Test. J Clin Psychol. 1998;54(5):585–591.
  17.  Miner T, Ferraro FR. The role of speed of processing, inhibitory 
mechanisms, and presentation order in trail-making test performance. 
Brain Cogn. 1998;38(2):246–253.
  18.  Arbuthnott K, Frank J. Trail making test, part B as a measure of 
executive control: validation using a set-switching paradigm. J Clin 
Exp Neuropsychol. 2000;22(4):518–528.
  19.  Gaudino EA, Geisler MW, Squires NK. Construct validity in the Trail 
Making Test: what makes Part B harder? J Clin Exp Neuropsychol. 
1995;17(4):529–535.
  20.  Sánchez-Cubillo I, Periáñez JA, Adrover-Roig D, et al. Construct 
validity of the Trail Making Test: role of task-switching, working 
memory, inhibition/interference control, and visuomotor abilities.   
J Int Neuropsychol Soc. 2009;15(3):438–450.
  21.  Periáñez JA, Ríos-Lago M, Rodríguez-Sánchez JM, et al. Trail Mak-
ing Test in traumatic brain injury, schizophrenia, and normal ageing: 
sample comparisons and normative data. Arch Clin Neuropsychol. 
2007;22(4):433–447.
  22.  Stuss DT, Bisschop SM, Alexander MP, Levine B, Katz D, Izukawa D. 
The Trail Making Test: a study in focal lesion patients. Psychol Assess. 
2001;13(2):230–239.
  23.  Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from 
the early discoveries to the potential clinical use. J Transl Med. 
2012;10:239.
  24.  Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer’s 
disease: role of axonal transport. Gene Brain Behav. 2008;7 Suppl 1: 
43–56.
  25.  White HK, Levin ED. Four-week nicotine skin patch treatment effects 
on cognitive performance in Alzheimer’s disease.   Psychopharmacology. 
1999;143(2):158–165.
  26.  French KL, Granholm AC, Moore AB, Nelson ME,   Bimonte-Nelson HA. 
Chronic nicotine improves working and reference memory performance 
and reduces hippocampal NGF in aged female rats. Behav Brain Res. 
2006;169(2):256–262.
  27.  Hernandez CM, Terry AV Jr. Repeated nicotine exposure in rats: effects 
on memory function, cholinergic markers and nerve growth factor. 
Neuroscience. 2005;130(4):997–1012.
  28.  Health Quality Ontario. Vitamin B12 and cognitive function: an 
evidence-based analysis. Ont Health Technol Assess Ser. 2013;13(23): 
1–45.
  29.  Lu’o’ng KV, Nguyen LT. The beneficial role of vitamin D in Alzheimer’s 
disease. Am J Alzheimers Dis Other Demen. 2011;26(7):511–520.
  30.  Olson CR, Mello CV. Significance of vitamin A to brain function, 
behavior and learning. Mol Nutr Food Res. 2010;54(4):489–495.
  31.  Lane JT. The role of retinoids in the induction of nerve growth 
factor: a potential treatment for diabetic neuropathy. Transl Res. 
2014;164(3):193–195.
  32.  Scalabrino G, Mutti E, Veber D, et al. Increased spinal cord NGF 
levels in rats with cobalamin (vitamin B12) deficiency. Neurosci Lett. 
2006;396(2):153–158.